Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The AAP says greater access and education are critical in curbing STIs.
Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.
The diagnostics firm is undercutting Myriad's cost by almost $1,000.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
The second-line drug sped from Priority Review status for the first-line indication to approval in just over two months.
Researchers surveying 21 Long Island mammography centers found that women do not know their risk.
The drug maker brought together a group of five established healthcare advocates under the umbrella GLAM, short for Great Life After Menopause. The advocates will keep their distinct voices, which are anything but muted.
The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.
J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.
The first prescription non-hormonal treatment offers relief for women who do not want to tangle with hormone-replacement therapy.
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director's Q&A
The first drug for morning sickness in thirty years enters the market this month.
Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
The regulator tells manufacturers to halve the recommended doses of zolpidem sleep-aids. Purdue Pharma's Intermezzo already hits the mark, but the drugmaker doesn't anticipate a sales jump or new messaging strategy.
Bayer scores the first IUD approval in 12 years, EMA raises rates on pharma.
The drugmaker is focusing on two different parts of motherhood—pre and post—in dual fall campaigns that seek to emphasize preventive health across ages.
Hormone replacement therapy took another hit yesterday as a task force advised post-menopausal women to avoid the drugs due to health risks.
Desperate Housewives star Dana Delany will serve as the face of Pfizer's "Women Move the World" campaign for OTC supplement Caltrate. In a twist on the user-generated content formula, she'll invite women to submit their girl power-themed stories to the brand's Facebook page for consideration as advertising fodder
A feminine hygiene brand known for its boffo advertising is back with an anatomically-explicit ad campaign that's generating tons of publicity but also charges of racism.
The percentage of women surveyed that said they're buying prescription medications was way up in 2010 - to 64% from 48% in 2009 - a jump the survey's sponsors, Saatchi & Saatchi Wellness and Time Inc.'s Health, said points to a recessionary refocusing on personal health with great potential for healthcare marketers.
Forty-four percent of women research prescribed drugs using multiple sources before filling a script, a survey found, suggesting that marketing efforts targeting Baby Boomer women, in particular, must focus less on brand awareness and more on the post-script conversation.